NF1
NF1 encodes neurofibromin, a large RAS GTPase-activating protein (GAP) that accelerates the intrinsic GTP hydrolysis of active RAS, converting it to the inactive GDP-bound state and thus serving as a critical brake on MAPK/ERK and PI3K/mTOR proliferation signaling. Germline NF1 loss-of-function mutations cause Neurofibromatosis type 1, the most common single-gene disorder predisposing to nervous system tumors, characterized by cafe-au-lait spots, cutaneous and plexiform neurofibromas, optic pathway gliomas, and an elevated lifetime risk of malignant peripheral nerve sheath tumors. The MEK inhibitor selumetinib (Koselugo) achieved the first targeted therapy approval specifically for NF1-associated pediatric inoperable plexiform neurofibromas, demonstrating that blocking the hyperactive MAPK pathway can shrink these tumors.
Key Takeaways
- •NF1 encodes neurofibromin, a critical negative regulator of the RAS signaling pathway that acts as a RAS-GAP.
- •Loss of NF1 function leads to constitutive RAS activation, driving unchecked cellular growth, survival, and tumor formation.
- •Germline NF1 mutations cause Neurofibromatosis Type 1, a multi-system disorder characterized by nerve tumors, skin changes, and skeletal issues.
- •MEK inhibitors (e.g., Selumetinib) are the first targeted therapies approved to shrink inoperable plexiform neurofibromas.
Basic Information
- Gene Symbol
- NF1
- Full Name
- Neurofibromin 1
- Also Known As
- NFNSVRNFWSS
- Location
- 17q11.2
- Protein Type
- RAS-GAP
- Protein Family
- GTPase-activating proteins
Related Isoforms
Key SNPs
Pathogenic variant associated with a "mild" NF1 phenotype (café-au-lait spots without neurofibromas).
Known pathogenic variant typically resulting in a milder clinical course and lack of externally visible tumors.
Common marker polymorphism frequently used in genetic mapping and population studies of the NF1 locus.
Modifier SNP associated with an increased risk of high-grade gliomas in patients with NF1 mutations.
Genetic modifier linked to telomere maintenance and brain tumor susceptibility in the NF1 population.
Modifier SNP involved in cell cycle regulation that influences the risk of malignant tumor transformation.
Overview
The NF1 gene encodes neurofibromin, a large, multifunctional protein that serves as a master negative regulator of the RAS signaling pathway. Neurofibromin functions as a GTPase-activating protein (GAP) that catalyzes the conversion of active RAS-GTP (the "on" state) into inactive RAS-GDP (the "off" state). By checking RAS activity, NF1 prevents the unchecked transmission of growth signals to downstream cascades like MAPK and PI3K.
Because RAS is a central hub for cellular growth and differentiation, the loss of neurofibromin has profound effects across multiple systems. NF1 is considered a "classic" tumor suppressor; its absence allows for the formation of tumors along nerves (neurofibromas), brain tissue (gliomas), and malignant nerve sheath tumors, while also disrupting skeletal and cognitive development.
Conceptual Model
A simplified mental model for the pathway:
Neurofibromin is the mandatory finger that pushes the RAS switch back to "Off." Without it, the signal for growth never stops.
Core Health Impacts
- • Growth regulation: Maintains the "resting state" of cellular growth signaling pathways.
- • Tumor defense: Primary defense against the formation of benign and malignant nerve tumors.
- • Skeletal health: Essential for normal skeletal development and bone mineral density.
- • Synaptic plasticity: Regulates synaptic plasticity and cognitive function in the brain.
- • Glioma suppression: Suppresses the development of high-grade gliomas and glioblastoma.
- • Cytoskeleton dynamics: Coordinates actin cytoskeleton dynamics via interaction with LIMK1.
Protein Domains
GAP-Related Domain
The catalytic core (GRD). It provides the "arginine finger" that accelerates RAS-GTP hydrolysis by over 1,000-fold.
Sec14 / PH Domain
A lipid-binding module. It helps anchor neurofibromin to membranes and may regulate its ability to capture RAS molecules.
C-terminal Domain
The regulatory tail. Contains binding sites for kinases and scaffolding proteins like SPRED1 that control neurofibromin recruitment.
Upstream Regulators
RAS-GTP (Substrate) Activator
The active, growth-driving form of RAS; neurofibromin must bind to it to trigger the "off" switch.
SPRED1 Activator
Essential scaffolding protein that recruits neurofibromin to the cell membrane to interact with its RAS substrates.
PKC (Protein Kinase C) Activator
Phosphorylates neurofibromin, potentially modulating its GAP activity in response to cellular stress.
PKA (Protein Kinase A) Activator
Kinase involved in the post-translational tuning of neurofibromin stability and localization.
Growth Factors (Antagonist) Activator
Signals from receptors generate RAS-GTP, which neurofibromin must continuously work to counter.
14-3-3 Proteins Activator
Interact with phosphorylated neurofibromin to regulate its function and subcellular partitioning.
Downstream Targets
RAS-GDP Activates
The inactive product; neurofibromin accelerates the conversion of active RAS back to this resting state.
MEK / ERK Inhibits
Indirect targets; the primary MAPK growth cascade that becomes hyperactive when neurofibromin is lost.
PI3K / AKT Inhibits
Indirectly checked survival pathway; neurofibromin prevents excessive activation of this anabolic axis.
mTOR Inhibits
Downstream of the PI3K axis; its overactivation in NF1-deficient cells drives protein synthesis and tumor growth.
LIMK1 Activates
Neurofibromin interacts with LIMK1 to regulate actin cytoskeleton dynamics and neuronal morphology.
Tubulin Activates
Neurofibromin binds to microtubules, influencing intracellular transport and mitotic spindle organization.
Role in Aging
NF1 function is essential for preventing Premature Cellular Senescence and age-related tissue breakdown. Because RAS signaling drives the SASP (senescence-associated secretory phenotype), maintaining the neurofibromin brake is vital for healthy longevity.
RAS-MAPK Tone
Chronic hyperactivation of the RAS pathway is a hallmark of aged cells. Neurofibromin prevents this "noisy" signaling from triggering chronic inflammation and tissue aging.
Cognitive Resilience
Neurofibromin regulates synaptic signaling in the hippocampus. Age-related decline in NF1 function can impair learning and memory, contributing to cognitive frailty.
Skeletal Longevity
NF1 loss accelerates the breakdown of bone (osteopenia). Maintaining neurofibromin function ensures that bone mineral density is preserved as the body ages.
Stem Cell Homeostasis
RAS signaling must be perfectly tuned for stem cells to self-renew without transforming. NF1 provides the mandatory check that prevents stem cell exhaustion or malignancy.
Vascular Health
Proper RAS regulation by NF1 is essential for maintaining the smooth muscle and endothelial lining of blood vessels, preventing age-related vasculopathy.
Senescence Drive
Loss of the NF1 brake can drive cells into a permanent state of senescence, where they secrete inflammatory factors that damage neighboring healthy tissue (inflammaging).
Disorders & Diseases
Neurofibromatosis Type 1
A common genetic disorder (1 in 3,000 births) caused by germline mutations. Characterized by a highly variable clinical course affecting the skin, nervous system, and skeleton.
Malignant Peripheral Nerve Sheath Tumor (MPNST)
The most aggressive complication of NF1 syndrome. These cancers arise from pre-existing plexiform neurofibromas and are driven by the complete loss of neurofibromin and secondary genetic hits.
Glioblastoma (Mesenchymal Subtype)
Somatic loss of NF1 is a hallmark of the Mesenchymal subtype of sporadic glioblastoma. These tumors are highly aggressive, showing intense immune infiltration and poor treatment response.
Skeletal Dysplasia & Osteopenia
NF1 loss in bone cells leads to congenital pseudarthrosis (non-healing fractures) and a systemic reduction in bone mineral density, significantly increasing fracture risk.
Cognitive & Behavioral Phenotypes
Up to 50% of children with NF1 mutations experience learning disabilities or ADHD. These are driven by the overactive RAS signaling at the synapse, which disrupts the balance of neurotransmitter release.
Interventions
Supplements
Standard recommendation; NF1 patients are highly prone to low levels and associated bone mineral density loss.
Polyphenol being investigated for potential anti-inflammatory effects on cutaneous neurofibroma growth.
May support general metabolic and cardiovascular health in the context of chronic growth signaling.
Studied in combination with curcumin for its potential to modulate NF1-related pathways in clinical trials.
Works with Vitamin D to combat the early-onset osteopenia and osteoporosis frequently seen in NF1.
Lifestyle
Critical for maintaining bone density and muscle strength, which are often impaired in NF1 syndrome.
Encouraged in moderation to help maintain natural Vitamin D stores, often low in the NF1 population.
Rich in antioxidants and healthy fats to support cellular health and manage systemic inflammation.
The most vital "lifestyle" habit for early detection of optic gliomas and malignant nerve sheath tumors.
Medicines
The first FDA-approved MEK inhibitor specifically for pediatric inoperable plexiform neurofibromas.
Recently approved MEK inhibitor for both adults and children with symptomatic, inoperable plexiform tumors.
Sometimes used to slow the metabolic drive of neurofibromas by targeting the downstream mTOR axis.
Frequently prescribed to manage the neuropathic pain associated with large or deep neurofibromas.
Lab Tests & Biomarkers
Genetic Testing
High-accuracy NGS screening to confirm a clinical diagnosis of Neurofibromatosis Type 1.
Detects cryptic splicing mutations that are often missed by standard DNA sequencing.
Ordered for patients with "mild" symptoms to rule out Legius syndrome (an NF1 mimic).
Activity Markers
Laboratory assay to measure the actual level of active RAS in tissue or cell culture.
Tissue marker for MAPK pathway hyperactivation; used to assess MEK inhibitor efficacy.
Immunohistochemistry to verify the physical presence or complete loss of the NF1 protein.
Clinical Monitoring
Critical annual screen; patients require aggressive supplementation to maintain healthy levels.
Used to accurately measure the growth or shrinkage of internal plexiform neurofibromas.
Assesses bone mineral density; recommended early in NF1 patients to manage fracture risk.
Hormonal Interactions
Vitamin D Metabolic Protector
Functions as a hormone that is essential for bone health; deficiency is a hallmark of the NF1 phenotype.
Estrogen Growth Modifier
Increased estrogen levels during puberty or pregnancy are often correlated with rapid neurofibroma growth.
Growth Hormone Indirect Driver
Systemic growth signaling can synergize with NF1 loss to accelerate the expansion of benign tumors.
Progesterone Tissue Modifier
May interact with neurofibromin signaling in reproductive tissues and nerve sheath environments.
Insulin Metabolic Balancer
Hyperinsulinemia can amplify the overactive RAS signaling caused by neurofibromin deficiency.
Cortisol Stress Interaction
Chronic stress can exacerbate the learning and cognitive challenges often associated with NF1 function.
Deep Dive
Network Diagrams
The RAS-GAP Inactivation Cycle
NF1 Signaling & Treatment Architecture
The RAS-GAP Brake: Neurofibromin’s Catalytic “Arginine Finger”
The most vital region of the neurofibromin protein is the GAP-Related Domain (GRD). RAS is a molecular switch that slowly turns itself off, but neurofibromin makes that process 1,000 times faster.
The Mechanism: Neurofibromin provides a specific amino acid (Arginine 1276), known as the “arginine finger,” which reaches into the RAS active site. This arginine facilitates the chemical reaction that breaks down GTP into GDP, instantly killing the growth signal.
Loss of Control: When neurofibromin is mutated, the “finger” is gone. RAS stays in the active, GTP-bound state for far too long, constantly telling the cell to divide and survive, even when no growth factors are present.
The Membrane Gate: SPRED1 and the Legius Mimic
Neurofibromin cannot function if it cannot find the cell membrane. It relies on a partner protein called SPRED1 to act as its GPS and anchor.
SPRED1 Recruitment: SPRED1 binds to the C-terminal of neurofibromin and pulls it to the membrane where RAS is located. If SPRED1 is mutated, neurofibromin remains “lost” in the cytoplasm, unable to reach the RAS switch.
Legius Syndrome: Mutations in SPRED1 cause a condition called Legius Syndrome. These patients have the same café-au-lait spots as NF1 patients (because the RAS pathway is overactive), but they never develop neurofibromas because enough neurofibromin still reaches its targets in nerve tissue via secondary mechanisms.
The MEK Revolution: Transforming the NF1 Clinical Pathway
For over a century, there was no medicine for NF1 tumors. The discovery that MEK is the primary bottleneck for RAS signals changed everything.
Pathway Logic: Because NF1 loss makes RAS hyperactive, the entire downstream cascade (RAS -> RAF -> MEK -> ERK) is flooded with signal. MEK is the narrowest point in this cascade.
Clinical Efficacy: Drugs like Selumetinib block MEK, effectively cutting off the signal that RAS is sending. In the 2020 SPRINT trial, over 70% of children with massive, life-threatening plexiform tumors saw their tumors shrink for the first time in history.
Diagnostic Note: The "Dose" of Neurofibromin
Haploinsufficiency: NF1 is a haploinsufficient gene. Just losing one of your two copies (leaving 50% protein) is enough to cause learning issues and skin spots. However, a tumor only forms when a specific cell loses its second copy (the "two-hit" model).
Variable Expressivity: Even within the same family with the same mutation, one person may have mild skin spots while another has severe tumors, highlighting the massive role of unknown genetic modifiers and environmental factors in NF1 biology.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
One of the landmark papers identifying the NF1 gene through positional cloning of translocation breakpoints.
First established the functional identity of neurofibromin as a RAS-GTPase activating protein.
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Proved that loss of NF1 leads to constitutively active, GTP-bound RAS in human malignant tumors.
The definitive clinical trial demonstrating that MEK inhibition can significantly shrink NF1-associated tumors.
Provided the complete cDNA sequence and identified the first pathogenic point mutations in NF1 patients.
Characterized the high-affinity biochemical interaction between the neurofibromin GAP domain and RAS.